Annual EBIT
$5.18 M
-$62.63 M-92.36%
December 31, 2023
Summary
- As of February 7, 2025, SUPN annual earnings before interest & taxes is $5.18 million, with the most recent change of -$62.63 million (-92.36%) on December 31, 2023.
- During the last 3 years, SUPN annual EBIT has fallen by -$187.22 million (-97.31%).
- SUPN annual EBIT is now -97.31% below its all-time high of $192.40 million, reached on December 31, 2020.
Performance
SUPN EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$44.94 M
+$18.64 M+70.87%
September 30, 2024
Summary
- As of February 7, 2025, SUPN quarterly earnings before interest & taxes is $44.94 million, with the most recent change of +$18.64 million (+70.87%) on September 30, 2024.
- Over the past year, SUPN quarterly EBIT has increased by +$35.05 million (+354.47%).
- SUPN quarterly EBIT is now -23.57% below its all-time high of $58.80 million, reached on September 30, 2020.
Performance
SUPN Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$72.48 M
+$35.05 M+93.67%
September 30, 2024
Summary
- As of February 7, 2025, SUPN TTM earnings before interest & taxes is $72.48 million, with the most recent change of +$35.05 million (+93.67%) on September 30, 2024.
- Over the past year, SUPN TTM EBIT has increased by +$31.55 million (+77.09%).
- SUPN TTM EBIT is now -62.51% below its all-time high of $193.30 million, reached on September 30, 2020.
Performance
SUPN TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
SUPN EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -92.4% | +354.5% | +77.1% |
| 3 y3 years | -97.3% | +354.5% | +77.1% |
| 5 y5 years | -96.7% | +354.5% | +77.1% |
SUPN EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -94.6% | at low | at high | +377.1% | -25.0% | +1522.5% |
| 5 y | 5-year | -97.3% | at low | -23.6% | +377.1% | -62.5% | +1522.5% |
| alltime | all time | -97.3% | +106.1% | -23.6% | +278.3% | -62.5% | +185.8% |
Supernus Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $44.94 M(+70.9%) | $72.48 M(+93.7%) |
| Jun 2024 | - | $26.30 M(>+9900.0%) | $37.42 M(-834.5%) |
| Mar 2024 | - | $243.00 K(-75.5%) | -$5.09 M(-198.3%) |
| Dec 2023 | $5.18 M(-92.4%) | $990.00 K(-90.0%) | $5.18 M(-87.3%) |
| Sep 2023 | - | $9.89 M(-161.0%) | $40.93 M(+26.6%) |
| Jun 2023 | - | -$16.22 M(-254.1%) | $32.32 M(-47.6%) |
| Mar 2023 | - | $10.52 M(-71.4%) | $61.67 M(-9.1%) |
| Dec 2022 | $67.81 M(-29.8%) | $36.73 M(+2769.8%) | $67.81 M(+73.6%) |
| Sep 2022 | - | $1.28 M(-90.3%) | $39.06 M(-46.2%) |
| Jun 2022 | - | $13.13 M(-21.2%) | $72.67 M(-24.5%) |
| Mar 2022 | - | $16.66 M(+108.7%) | $96.24 M(-0.4%) |
| Dec 2021 | $96.60 M(-49.8%) | $7.99 M(-77.1%) | $96.60 M(-28.1%) |
| Sep 2021 | - | $34.88 M(-5.0%) | $134.40 M(-15.1%) |
| Jun 2021 | - | $36.70 M(+115.6%) | $158.32 M(-9.3%) |
| Mar 2021 | - | $17.03 M(-62.8%) | $174.64 M(-9.2%) |
| Dec 2020 | $192.40 M(+13.0%) | $45.79 M(-22.1%) | $192.40 M(-0.5%) |
| Sep 2020 | - | $58.80 M(+10.9%) | $193.30 M(+7.5%) |
| Jun 2020 | - | $53.02 M(+52.4%) | $179.75 M(+2.8%) |
| Mar 2020 | - | $34.79 M(-25.5%) | $174.87 M(+2.7%) |
| Dec 2019 | $170.19 M(+7.5%) | $46.69 M(+3.2%) | $170.19 M(+1.4%) |
| Sep 2019 | - | $45.25 M(-6.0%) | $167.86 M(+2.0%) |
| Jun 2019 | - | $48.13 M(+59.9%) | $164.55 M(+5.6%) |
| Mar 2019 | - | $30.11 M(-32.1%) | $155.80 M(-1.6%) |
| Dec 2018 | $158.29 M(+54.9%) | $44.37 M(+5.8%) | $158.29 M(+6.1%) |
| Sep 2018 | - | $41.94 M(+6.5%) | $149.13 M(+14.5%) |
| Jun 2018 | - | $39.38 M(+20.8%) | $130.25 M(+10.8%) |
| Mar 2018 | - | $32.60 M(-7.4%) | $117.51 M(+15.0%) |
| Dec 2017 | $102.19 M | $35.21 M(+52.6%) | $102.19 M(+22.4%) |
| Sep 2017 | - | $23.07 M(-13.4%) | $83.48 M(+3.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $26.64 M(+54.3%) | $80.76 M(+21.9%) |
| Mar 2017 | - | $17.27 M(+4.7%) | $66.25 M(+19.5%) |
| Dec 2016 | $55.46 M(+186.2%) | $16.50 M(-18.9%) | $55.46 M(+17.4%) |
| Sep 2016 | - | $20.34 M(+67.7%) | $47.26 M(+46.5%) |
| Jun 2016 | - | $12.13 M(+87.2%) | $32.27 M(+35.0%) |
| Mar 2016 | - | $6.48 M(-21.9%) | $23.90 M(+23.3%) |
| Dec 2015 | $19.38 M(-514.6%) | $8.30 M(+55.2%) | $19.38 M(+13.9%) |
| Sep 2015 | - | $5.35 M(+42.0%) | $17.02 M(+55.9%) |
| Jun 2015 | - | $3.77 M(+91.8%) | $10.91 M(-6.1%) |
| Mar 2015 | - | $1.96 M(-66.9%) | $11.63 M(-348.8%) |
| Dec 2014 | -$4.67 M(-94.5%) | $5.94 M(-885.6%) | -$4.67 M(-84.9%) |
| Sep 2014 | - | -$756.00 K(-116.9%) | -$30.91 M(-39.8%) |
| Jun 2014 | - | $4.48 M(-131.3%) | -$51.38 M(-36.6%) |
| Mar 2014 | - | -$14.34 M(-29.4%) | -$81.07 M(-4.0%) |
| Dec 2013 | -$84.42 M(+97.7%) | -$20.30 M(-4.4%) | -$84.42 M(+9.9%) |
| Sep 2013 | - | -$21.23 M(-15.8%) | -$76.83 M(+12.6%) |
| Jun 2013 | - | -$25.21 M(+42.6%) | -$68.21 M(+31.0%) |
| Mar 2013 | - | -$17.69 M(+39.2%) | -$52.08 M(+21.9%) |
| Dec 2012 | -$42.71 M(+13.6%) | -$12.71 M(+0.8%) | -$42.71 M(+6.5%) |
| Sep 2012 | - | -$12.60 M(+38.7%) | -$40.10 M(+7.2%) |
| Jun 2012 | - | -$9.08 M(+9.2%) | -$37.41 M(+1.9%) |
| Mar 2012 | - | -$8.31 M(-17.6%) | -$36.72 M(-2.8%) |
| Dec 2011 | -$37.60 M(-4.7%) | -$10.10 M(+1.8%) | -$37.76 M(-19.8%) |
| Sep 2011 | - | -$9.91 M(+18.1%) | -$47.08 M(+26.7%) |
| Jun 2011 | - | -$8.40 M(-10.3%) | -$37.17 M(+29.2%) |
| Mar 2011 | - | -$9.36 M(-51.8%) | -$28.77 M(+48.2%) |
| Dec 2010 | -$39.47 M(-1053.9%) | -$19.41 M(+41.5%) | -$19.41 M(+41.5%) |
| Dec 2009 | $4.14 M(-116.7%) | -$13.72 M | -$13.72 M |
| Dec 2008 | -$24.80 M(+43.6%) | - | - |
| Dec 2007 | -$17.27 M | - | - |
FAQ
- What is Supernus Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual EBIT year-on-year change?
- What is Supernus Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly EBIT year-on-year change?
- What is Supernus Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals TTM EBIT year-on-year change?
What is Supernus Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of SUPN is $5.18 M
What is the all time high annual EBIT for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual earnings before interest & taxes is $192.40 M
What is Supernus Pharmaceuticals annual EBIT year-on-year change?
Over the past year, SUPN annual earnings before interest & taxes has changed by -$62.63 M (-92.36%)
What is Supernus Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of SUPN is $44.94 M
What is the all time high quarterly EBIT for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly earnings before interest & taxes is $58.80 M
What is Supernus Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, SUPN quarterly earnings before interest & taxes has changed by +$35.05 M (+354.47%)
What is Supernus Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of SUPN is $72.48 M
What is the all time high TTM EBIT for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high TTM earnings before interest & taxes is $193.30 M
What is Supernus Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, SUPN TTM earnings before interest & taxes has changed by +$31.55 M (+77.09%)